WallStreetZenWallStreetZen

NASDAQ: ENSC
Ensysce Biosciences Inc Stock

Open Broker Account
$2.27+0.12 (+5.58%)
Updated Dec 5, 2022
ENSC Price
$2.27
Fair Value Price
$4.60
Market Cap
$6.45M
52 Week Low
$1.90
52 Week High
$140.00
P/E
-0.11x
P/B
-1.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$28.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.41
Operating Cash Flow
-$18M
Beta
0.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ENSC Overview

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENSC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ENSC ($2.27) is undervalued by 50.7% relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ENSC ($2.27) is significantly undervalued by 50.7% relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ENSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENSC due diligence checks available for Premium users.

Be the first to know about important ENSC news, forecast changes, insider trades & much more!

ENSC News

Valuation

ENSC fair value

Fair Value of ENSC stock based on Discounted Cash Flow (DCF)
Price
$2.27
Fair Value
$4.60
Undervalued by
50.70%
ENSC ($2.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENSC ($2.27) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ENSC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.11x
Industry
14.34x
Market
21.63x

ENSC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.06x
Industry
4.96x

ENSC's financial health

Profit margin

Revenue
$0.0
Net Income
-$9.8M
Profit Margin
0%
ENSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$8.3M
Liabilities
$14.7M
Debt to equity
-2.41
ENSC's short-term liabilities ($11.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENSC's short-term assets ($7.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENSC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENSC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.7M
Investing
$0.0
Financing
$7.5M
ENSC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ENSC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ENSC$6.45M+5.58%-0.11x-1.06x
STAB$6.50M0.00%-0.05x-0.64x
XBIO$6.37M+4.48%-0.82x0.44x
TENX$6.35M+2.90%-0.38x1.61x
ENVB$6.23M-3.23%-0.03x0.27x

Ensysce Biosciences Stock FAQ

What is Ensysce Biosciences's quote symbol?

NASDAQ: ENSC) Ensysce Biosciences trades on the NASDAQ under the ticker symbol ENSC. Ensysce Biosciences stock quotes can also be displayed as NASDAQ: ENSC.

If you're new to stock investing, here's how to buy Ensysce Biosciences stock.

What is the 52 week high and low for Ensysce Biosciences (NASDAQ: ENSC)?

(NASDAQ: ENSC) Ensysce Biosciences's 52-week high was $140.00, and its 52-week low was $1.90. It is currently -98.38% from its 52-week high and 19.47% from its 52-week low.

How much is Ensysce Biosciences stock worth today?

(NASDAQ: ENSC) Ensysce Biosciences currently has 2,841,091 outstanding shares. With Ensysce Biosciences stock trading at $2.27 per share, the total value of Ensysce Biosciences stock (market capitalization) is $6.45M.

Ensysce Biosciences stock was originally listed at a price of $199.20 in Dec 1, 2017. If you had invested in Ensysce Biosciences stock at $199.20, your return over the last 5 years would have been -98.86%, for an annualized return of -59.14% (not including any dividends or dividend reinvestments).

How much is Ensysce Biosciences's stock price per share?

(NASDAQ: ENSC) Ensysce Biosciences stock price per share is $2.27 today (as of Dec 5, 2022).

What is Ensysce Biosciences's Market Cap?

(NASDAQ: ENSC) Ensysce Biosciences's market cap is $6.45M, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ensysce Biosciences's market cap is calculated by multiplying ENSC's current stock price of $2.27 by ENSC's total outstanding shares of 2,841,091.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.